MiR-3934-5p promotes proliferation of hepatocellular carcinoma cells by targeting LACTB

Yao XIAN; Runkun LIU; Huanye MO; Xuelian XIAO; Liang WANG; Lei ZHANG

doi:10.16016/j.1000-5404.202012245

您当前的位置：

首页 >

文章列表页 >

MiR-3934-5p promotes proliferation of hepatocellular carcinoma cells by targeting LACTB

Basic Medicine | 更新时间：2026-01-09

- MiR-3934-5p promotes proliferation of hepatocellular carcinoma cells by targeting LACTB
- Journal of Third Military Medical University Vol. 43, Issue 13, Pages: 1219-1226(2021)
- 作者机构：
  
  1.710061 西安，西安交通大学第一附属医院: 营养科
  2.710061 西安，西安交通大学第一附属医院: 肝胆外科
  3.710061 西安，西安交通大学第一附属医院: 老年外科
- 作者简介：
- 基金信息：
  
  the Key Research and Development Program of Shaanxi Province(2020SF-061);the Foundation of the First Affiliated Hospital of Xi'an Jiaotong University(2019ZYTS-07)
- DOI：10.16016/j.1000-5404.202012245
  CLC： R394.3;R730.23;R735.7
- Received：31 December 2020，
  
  Revised：2021-02-08，
  
  Published：15 July 2021
- 稿件说明：
移动端阅览
Yao XIAN, Runkun LIU, Huanye MO, et al. MiR-3934-5p promotes proliferation of hepatocellular carcinoma cells by targeting LACTB[J]. Journal of Third Military Medical University, 2021, 43(13): 1219-1226.
DOI：

Yao XIAN, Runkun LIU, Huanye MO, et al. MiR-3934-5p promotes proliferation of hepatocellular carcinoma cells by targeting LACTB[J]. Journal of Third Military Medical University, 2021, 43(13): 1219-1226. DOI： 10.16016/j.1000-5404.202012245.

摘要

目的

观察miR-3934-5p在肝细胞癌(hepatocellular carcinoma

HCC)中的表达，探讨其临床意义及分子机制。

方法

收集53例2013年9月至2014年8月在本院确诊的肝细胞癌患者的癌旁组织及肿瘤组织。实时定量PCR(RT-qPCR)检测组织和细胞miR-3934-5p的表达；应用人类癌症基因库(the Cancer Genome Atlas

TCGA)分析正常肝组织与肝癌组织中miR-3934-5p的表达；用χ

检验和Kaplan-Meier生存曲线分析miR-3934-5p与临床病理特征及生存预后之间的相关性；采用RT-qPCR和Western blot检测转染效率；CCK-8实验、平板克隆实验及EdU实验评价HCCLM3细胞的活性及增殖能力；分析HCC组织中β-内酰胺酶(beta-lactamases，LACTB) mRNA与miR-3934-5p表达的相关性；TargetScan数据库预测miR-3934-5p下游靶基因，通过荧光素酶报告基因实验加以验证。

结果

miR-3934-5p在肝癌组织及细胞中高表达(

0.05)，且其高表达与肿瘤大小、肿瘤数量、血管侵犯及TNM分期显著相关(

0.05)；与miR-3934-5p低表达组相比，miR-3934-5p高表达组的肝癌患者5年生存率更低；CCK-8实验、平板克隆实验及EdU实验结果证实: 敲减miR-3934-5p可显著抑制HCCLM3细胞的增殖能力(

0.05)；LACTB被证实是miR-3934-5p的直接作用靶点，且其介导了miR-3934-5p的生物学功能。

结论

miR-3934-5p通过靶向抑制抑癌基因LACTB的表达促进肝癌细胞的增殖能力。

Abstract

Objective

To explore the expression

clinical significance and molecular mechanism of miR-3934-5p in hepatocellular carcinoma (HCC).

Methods

HCC tissues and adjacent normal tissues were collected from 53 HCC patients diagnosed in our hospital from September 2013 to August 2014. Real-time quantitative PCR (RT-qPCR) was performed to detect the level of miR-3934-5p in the above tissues and human liver cell line L02 and HCC cell lines. The Cancer Genome Atlas (TCGA) database was used to analyze the expression of miR-3934-5p in normal liver tissues and HCC tissues;

Chi

-square test with Kaplan-Meier survival curve were applied to analyze the correlation of miR-3934-5p and clinicopathological characteristics and survival prognosis; RT-qPCR and Western blotting were adopted to detect transfection efficiency; CCK-8 assay

colony formation assay and EdU assay were employed respectively to evaluate the activity and proliferation of HCCLM3 cells; Spearman correlation analysis was applied to study the correlation between LACTB mRNA and miR-3934-5p expression i

n HCC tissues; TargetScan database was used to predict the downstream target genes of miR-3934-5p

and the prediction results was verified by luciferase reporter assay.

Results

MiR-3934-5p was highly expressed in the liver cancer tissues and cells (

0.05)

and its high expression was significantly correlated with tumor size (

=0.040)

tumor multiplicity (

=0.013)

vascular invasion (

=0.006)

and TNM stage (

=0.017); Compared to the low miR-3934-5p expression group

the HCC patients with high expression had poorer survival prognosis. CCK-8 assay

colony formation assay and EdU assay confirmed that knocking down miR-3934-5p notably inhibited the proliferation of HCCLM3 cells (

0.05). LACTB had been proved to be the direct target of miR-3934-5p

and mediated the biological effect of miR-3934-5p on HCC cells.

Conclusion

MiR-3934-5p promotes the proliferation of HCC cells by targeting tumor suppressor gene LACTB.

关键词

Keywords

references

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI:10.3322/caac.21492.

LI Y, WANG X Y, LI Z G, et al . MicroRNA-4651 represses hepatocellular carcinoma cell growth and facilitates apoptosis via targeting FOXP4[J ] . Biosci Rep, 2020, 40(6): BSR20194011. DOI:10.1042/BSR20194011..

MAJID A, WANG J X, NAWAZ M, et al . miR-124-3p suppresses the invasiveness and metastasis of hepatocarcinoma cells via targeting CRKL[J ] . Front Mol Biosci, 2020, 7: 223. DOI:10.3389/fmolb.2020.00223..

REN A J, WEN Z Z, ZHENG L J. Downregulation of miR-3934-5p enhances A549 cell sensitivity to cisplatin by targeting TP53INP 1 [J ] . Exp Ther Med, 2019, 18(3): 1653-1660. DOI:10.3892/etm.2019.7718.

YE W, LIANG F, YING C, et al . Downregulation of microRNA-3934-5p induces apoptosis and inhibits the proliferation of neuroblastoma cells by targeting TP53INP 1 [J ] . Exp Ther Med, 2019, 18(5): 3729-3736. DOI:10.3892/etm.2019.8007..

CUCCHI D, MAURO C. LACTB-mediated tumour suppression by increased mitochondrial lipid metabolism[J]. Cell Death Differ, 2017, 24(7): 1137-1139. DOI: 10.1038/cdd.2017.60.

KECKESOVA Z, DONAHER J L, DE COCK J, et al . LACTB is a tumour suppressor that modulates lipid metabolism and cell state[J ] . Nature, 2017, 543(7647): 681-686. DOI:10.1038/nature21408.

ZENG K, CHEN X, HU X, et al . LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation[J ] . Oncogene, 2018, 37(41): 5534-5551. DOI:10.1038/s41388-018-0352-7.

XUE C, HE Y, ZHU W, et al . Low expression of LACTB promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma[J ] . Am J Transl Res, 2018, 10(12): 4152-4162.

LI Y, ZHOU Y, MA L, et al . MiR-3677-3p promotes hepatocellular carcinoma progression via inhibiting GSK3β[J ] . Acta Biochim Biophys Sin (Shanghai), 2020, 52(12): 1404-1412. DOI:10.1093/abbs/gmaa125..

SI T, NING X J, ZHAO H W, et al . MicroRNA-9-5p regulates the mitochondrial function of hepatocellular carcinoma cells through suppressing PDK4[J ] . Cancer Gene Ther, 2020: 1-13. DOI:10.1038/s41417-020-00253-w.

DUAN X H, LI W, HU P, et al . MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma[J ] . Biosci Rep, 2020, 40(10): BSR20201761. DOI:10.1042/BSR20201761.

ZHAO Y C, ZHU C Q, CHANG Q, et al . MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F 7 [J ] . PLoS One, 2020, 15(11): e0242179. DOI:10.1371/journal.pone.0242179..

WANG Q, YANG X, ZHOU X, et al . MiR-3174 promotes proliferation and inhibits apoptosis by targeting FOXO1 in hepatocellular carcinoma[J ] . Biochem Biophys Res Commun, 2020, 526(4): 889-897. DOI:10.1016/j.bbrc.2020.03.152.

YAO B W, NIU Y S, LI Y Z, et al . High-matrix-stiffness induces promotion of hepatocellular carcinoma proliferation and suppression of apoptosis via miR-3682-3p-PHLDA1-FAS pathway[J ] . J Cancer, 2020, 11(21): 6188-6203. DOI:10.7150/jca.45998..

XIAN Y, WANG L, YAO B, et al . MicroRNA-769-5p contributes to the proliferation, migration and invasion of hepatocellular carcinoma cells by attenuating RYBP[J ] . Biomed Pharmacother, 2019, 118: 109343. DOI:10.1016/j.biopha.2019.109343.

张雷, 王宇锋, 王亮, 等. miR-130b-3p通过靶向作用于INTS6促进肝细胞癌生长和转移[J]. 山西医科大学学报, 2019, 50(5): 543-550. DOI: 10.13753/j.issn.1007-6611.2019.05.003.

ZHANG L, WANG Y F, WANG L, et al . The miR-130b-3p promotes metastasis and proliferation of hepatocellular carcinoma by targeting INTS6[J ] . J Shanxi Med Univ, 2019, 50(5): 543-550, DOI: 10.13753/j.issn.1007-6611.2019.05.003.

YU Y, MIN Z, ZHOU Z, et al . Hypoxia-induced exosomes promote hepatocellular carcinoma proliferation and metastasis via miR-1273f transfer[J ] . Exp Cell Res, 2019, 385(1): 111649. DOI: 10.1016/j.yexcr.2019.111649..

POLIANSKYTE Z, PEITSARO N, DAPKUNAS A, et al . LACTB is a filament-forming protein localized in mitochondria[J ] . Proc Natl Acad Sci USA, 2009, 106(45): 18960-18965. DOI:10.1073/pnas.0906734106.

LI H T, DONG D Y, LIU Q, et al . Overexpression of LACTB, a mitochondrial protein that inhibits proliferation and invasion in glioma cells[J ] . Oncol Res, 2019, 27(4): 423-429. DOI:10.3727/096504017X15030178624579.

LANG V, PALLARA C, ZABALA A, et al . Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity[J ] . Mol Oncol, 2014, 8(5): 1026-1042. DOI:10.1016/j.molonc.2014.04.002.

RUSSO A, ESPOSITO D, CATILLO M, et al . Human rpL3 induces G 1 /S arrest or apoptosis by modulating p21 (Waf1/cip1) levels in a p53-independent manner[J ] . Cell Cycle, 2013, 12(1): 76-87. DOI:10.4161/cc.22963..

WALERYCH D, LISEK K, SOMMAGGIO R, et al . Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer[J ] . Nat Cell Biol, 2016, 18(8): 897-909. DOI:10.1038/ncb3380.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

GPX7 regulates proliferation and senescence of hepatocellular carcinoma cells through the PI3K-AKT pathway

UHRF2 promotes migration and proliferation of human hepatocellular carcinoma cells by PI3K/Akt signaling pathway

Ring finger protein 14 promotes proliferation, migration and invasion of hepatoma cells by inhibiting hepatocyte nuclear factor-1α

Roles and mechanisms of long non-coding RNA EHHADH-AS1 in HBV+ hepatocellular carcinoma

miR-134 suppresses proliferation in hepatocellular carcinoma cells by down-regulating FOXM1

Related Author

WANG Ruiguan

WANG Jing

YAN Maohui

LI Xinji

SUN Zhijia

Fengjuan CHENG

Jingjie SUN

Xianyun FANG

Related Institution

Faculty of Hepatobiliary and Pancreatic Surgery， First Medical Center， General Hospital of PLA， Beijing, Air Force Medical Center of PLA

Department of Hepatobiliary Surgery， Eighth Medical Center， General Hospital of PLA， Beijing, Air Force Medical Center of PLA

Department of Radiation Oncology, Air Force Medical Center of PLA

Department of Cell Biology and Genetics, Molecular Medicine and Cancer Research Center, College of Basic Medical Sciences, Chongqing Medical University

Department of Hepatobillary Surgery, the First Affiliated Hospital of Chongqing Medical University

⁰